A case of complete remission after palliative chemotherapy for pancreatic cancer

Jae Jin Lee, Han Taek Jeong, and Ji min Han
Department of Internal Medicine, Daegu Catholic University School of Medicine
Email: sunrise127@naver.com
Female, 61 years old

Chief complaint
- Indigestion for 1 month

Present illness
- 2022.02.03 Outside hospital
  - Indigestion, Weight loss 2kg for 1 month
  - USG/CT (22.02.15) → Pancreatic head cancer, 1.8cm
- 2022.2.17 DCUMC
  - EUS-FNB (22.02.21) → Cytology: adenocarcinoma, suggestive of CA 19-9 3965, CEA 38.2
Female, 61 years old

Past Medical history
HTN / Dyslipidemia / Hepatitis/ Tb: (+/+/-/-)

Family history: none

Operation history: none

Social history
Smoking: none
Alcohol: none
Outside hospital CT (2022.02.15)
 CBC: 7,100µl – 13.1g/dl – 283000/µl
PT/aPTT: 11.7sec / 23.6 sec
AST/ALT: 15 U/L / 12 U/L, ALP: 117 U/L
T-bil: 0.5 mg/dL, D-bil: <0.2 mg/dL
Amylase/Lipase: 49 U/L / 29 U/L
BUN/Cr: 8.9 mg/dL / 0.6 mg/dL
CA 19-9 : 3965 U/mL
CEA: 38.2 ng/mL
EUS-FNB needle: 25 gauge, 5 passes
Pancreas MRI (2022.03.02)
Clinical course - 1

Final diagnosis
Pancreatic cancer, cT4N1M1, stage IV

Plan
Palliative chemotherapy
ECOG PS : 0
1\textsuperscript{st} line : FOLFIRINOX
**Clinical course - 1**

FOLFIRINOX L1C1D1=22.03.03

FOLFIRINOX L1C3D1=22.04.01 (75% Dose reduction d/t neutropenia and peripheral neuropathy)

FOLFIRINOX (75%) L1C5D1=22.04.29 (PR)

Mass size 2.6 cm $\rightarrow$ 1.5cm

Metastatic nodule size decreased
(Liver S6)

Lymph node size decreased
(Portocaval)

CA 19-9/CEA 595 U/mL / 4.82 ng/mL
Clinical course - 1

FOLFIRINOX L1C1D1=22.03.03
FOLFIRINOX L1C3D1=22.04.01 (75% Dose reduction d/t neutropenia and peripheral neuropathy)
FOLFIRINOX (75%) L1C5D1=22.04.29 (PR)
FOLFIRINOX (75%) L1C9D1=22.06.23 (PR)

Mass size 1.5 cm → 1.1 cm
Metastatic nodule disappeared
(Liver S6)
Lymph node size decreased
(Portocaval)

CA 19-9/CEA 26 U/mL / 2.44 ng/mL
Clinical course - 1

FOLFIRINOX L1C1D1=22.03.03
FOLFIRINOX L1C3D1=22.04.01 (75% Dose reduction d/t neutropenia and peripheral neuropathy)
FOLFIRINOX (75%) L1C5D1=22.04.29 (PR)
FOLFIRINOX (75%) L1C9D1=22.06.23 (PR)
FOLFIRINOX (75%) L1C17D1=22.10.20 (CR)

No visible mass

CA 19-9/CEA 23 U/mL / 2.76 ng/mL
Clinical course - 2

Chemotherapy

FOLFIRINOX (75%) L1C24D1 = 2023.01.26

Pre-OP evaluation

PET CT (23.02.27)
- Almost disappeared hypermetabolic lesions in pancreatic head, peripancreatic lymph node and right lobe of liver
- No evidence of abnormal hypermetabolic lesion, suggesting distant metastasis

Liver MRI (23.02.27)
- Markedly decreased p-head cancer and Hepatic metastasis in S6.
Clinical course-

Pylorus preserving pancreaticoduodenectomy (23.03.27)

Adjuvant chemotherapy

Gemcitabine C1D1 = 2023.05.10
Gemcitabine C1D8 = 2023.05.17

Atypical gland, but no evidence of residual tumor
Pancreatic cancer, cT4N1M1, stage IV

Palliative chemotherapy

FOLFIRINOX L1C1~C2 (22.03.03~03.17)
75% FOLFIRINOX L1C3~C24 (22.04.01~23.01.26)

BPCT(23.02.08)

No visible primary tumor of pancreatic head

PET CT, MRI(23.02.27)

No metastasis

PPPD (23.03.27)

Tumor regression grade : Near total regression
Postoperative staging: pT1aN0M0, stage IA

Adjuvant chemotherapy

Gemcitabine C1D1 on 2023.05.10, C1D8 on 2023.05.17
Thank you for your attention